Bryan Johnson reports advanced meibomian gland dysfunction and a 4-treatment eye protocol

On 18 August 2026, Bryan Johnson reported a new eye diagnosis and treatment series. He says an ophthalmologist, Dr Amir Moarefi, found advanced meibomian gland dysfunction (MGD), tear production under 10 mm in 5 minutes in both eyes, and substantial meibomian-gland dropout on infrared meibography. He links the condition to evaporative dry eye and concurrent aqueous deficiency. The intervention bundle combines intense pulsed light, radiofrequency, manual gland expression, intraductal probing, and 630 nm low-level light therapy. He also reports warm compresses, preservative-free and lipid-replacement drops, prescription anti-inflammatory drops, a compounded azithromycin spray, moisture-chamber glasses, tear stimulation, omega-3, and lutein. Johnson says imaging showed a 30% improvement in gland function, with less irritation and less resistance during probing. The design has no control condition, no prespecified primary endpoint, no independent assessor, and several treatments started together. He therefore cannot identify which component produced the change. The post labels intraductal probing as experimental and describes future plans involving androgen, growth-factor, or organoid approaches that have not been tested in humans. This is a detailed n=1 medical report, not evidence that the combined protocol reverses gland loss or dry eye in other people. The reported tear values and imaging results need clinical records and repeat measurements for independent assessment.

Given that I did four therapies at the same time: IPL, RF, probing, and low level light therapy, I can’t determine which therapy did what.